Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405


Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.

Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS.

BJU Int. 2013 Mar;111(3):396-403. doi: 10.1111/j.1464-410X.2012.11295.x. Epub 2012 Jun 15.


Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC.

J Clin Oncol. 2010 Jun 10;28(17):2810-6. doi: 10.1200/JCO.2009.25.7311. Epub 2010 May 3.


Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.

Ng MK, Van As N, Thomas K, Woode-Amissah R, Horwich A, Huddart R, Khoo V, Thompson A, Dearnaley D, Parker C.

BJU Int. 2009 Apr;103(7):872-6. doi: 10.1111/j.1464-410X.2008.08116.x. Epub 2008 Oct 16.


Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.


A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.


Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.

Kotb AF, Tanguay S, Luz MA, Kassouf W, Aprikian AG.

Prostate Cancer Prostatic Dis. 2011 Mar;14(1):53-7. doi: 10.1038/pcan.2010.36. Epub 2010 Oct 12.


Active surveillance for the management of prostate cancer in a contemporary cohort.

Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.

Cancer. 2008 Jun 15;112(12):2664-70. doi: 10.1002/cncr.23502.


The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.


Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.

Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.

J Urol. 2005 Dec;174(6):2191-6.


High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.

Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H.

BJU Int. 2012 Oct;110(7):993-7. doi: 10.1111/j.1464-410X.2012.10972.x. Epub 2012 Mar 6.


Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.


Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE.

BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30.


Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17.


Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.

Thomsen FB, Christensen IJ, Brasso K, Røder MA, Iversen P.

BJU Int. 2014 May;113(5b):E98-105. doi: 10.1111/bju.12367. Epub 2013 Oct 31.


Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H.

J Clin Oncol. 2009 Aug 1;27(22):3591-7. doi: 10.1200/JCO.2008.19.9794. Epub 2009 Jun 8.


Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.


Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.

Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.

BJU Int. 2008 Jan;101(2):165-9. Epub 2007 Sep 10.


Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M.

Urology. 2007 May;69(5):931-5.


Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.


[Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy].

Rodríguez-Patrón Rodríguez R, Mayayo Dehesa T, González Galán A, Zuccarino AL, García González R, Cuesta Roca C.

Arch Esp Urol. 2002 Dec;55(10):225-34. Spanish.

Items per page

Supplemental Content

Support Center